The latest report by IMARC Group, titled “Liquid Biopsy Market Report by Product And Service (Kits and Reagents, Platforms and Instruments, Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA, and Others), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Others), End User (Hospitals and Laboratories, Academic and Research Centers, and Others), and Region 2025-2033”, offers a comprehensive analysis of the industry, which comprises insights on the market.
Liquid Biopsy Market Growth Forecast:
The global liquid biopsy market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.2 Billion by 2033, exhibiting a growth rate (CAGR) of 12.82% during 2025-2033.
Top 3 factors affecting the growth of the liquid biopsy market:
- Increasing Prevalence of Cancer and the Need for Early Detection
The global incidence of cancer is rising, making early detection and diagnosis crucial for improving patient outcomes. Traditional tissue biopsies are invasive, costly, and not always feasible, especially for patients with inaccessible tumors or those who cannot undergo surgery. Liquid biopsies offer a minimally invasive alternative by analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or other biomarkers in blood or other bodily fluids. This allows for earlier cancer detection, monitoring of treatment response, and detection of recurrence, driving the demand for liquid biopsy technologies. The growing focus on early cancer screening programs and personalized medicine further fuels market growth.
- Technological Advancements in Liquid Biopsy Technologies
Significant advancements in molecular biology, genomics, and microfluidics have enabled the development of highly sensitive and specific liquid biopsy assays. These advancements include improved methods for isolating and analyzing ctDNA, CTCs, and other biomarkers, as well as the development of novel platforms for high-throughput analysis. The introduction of techniques like digital PCR, next-generation sequencing (NGS), and droplet digital PCR (ddPCR) has enhanced the accuracy and sensitivity of liquid biopsy tests, making them more reliable for clinical applications. Continuous innovation in liquid biopsy technologies is a key driver for market growth, enabling more accurate and efficient cancer diagnosis and monitoring.
- Growing Adoption of Personalized Medicine and Companion Diagnostics
The increasing adoption of personalized medicine, which tailors treatment to individual patients based on their genetic makeup and tumor characteristics, is driving the demand for liquid biopsies. Liquid biopsies can provide valuable information about tumor heterogeneity, drug resistance mutations, and other biomarkers that can guide treatment decisions. Furthermore, the use of liquid biopsies as companion diagnostics to identify patients who are likely to benefit from specific targeted therapies is also contributing to market growth. As the focus shifts towards more personalized and targeted cancer treatments, the demand for liquid biopsy tests as a crucial tool for patient stratification and treatment monitoring is expected to increase significantly.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/liquid-biopsy-market/requestsample
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V., Thermo Fisher Scientific Inc., etc.
Liquid Biopsy Market Report Segmentation:
Breakup By Product and Service:
- Kits and Reagents
- Platforms and Instruments
- Services
Kits and reagents are the dominant market segment due to their essential role in enabling accurate and widespread biomarker detection, making them fundamental components of diagnostic testing processes.
Breakup By Circulating Biomarker:
- Circulating Tumor Cells
- Extracellular Vesicles
- Circulating Tumor DNA
- Others
Circulating tumor cells (CTCs) hold the largest market share due to their critical role in providing real-time information on tumor dynamics and metastasis, making them invaluable for cancer monitoring and treatment decisions.
Breakup By Cancer Type:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
Lung cancer represents the largest application segment due to its high global incidence and mortality rates, generating substantial demand for early, non-invasive diagnostic tools such as liquid biopsies.
Breakup By End User:
- Hospitals and Laboratories
- Academic and Research Centers
- Others
Hospitals and laboratories are the dominant end-user segment, serving as primary centers for diagnostic testing and possessing the advanced technology required for performing and analyzing liquid biopsies.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America holds the leading market position due to a strong demand for liquid biopsies driven by its advanced healthcare infrastructure, high adoption rate of innovative diagnostic technologies, and significant investment in cancer research and personalized medicine.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5125&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment